1. Scrip

Bridge Bio Eyes Faster Pipeline Progress Through New Funds, Model

 
• By Jung Won Shin

A Series A funding for South Korean bioventure Bridge Biotherapeutics may encourage creation of “no research, development only” bioventures and early investments in the biotech sector.

SEOUL - Bridge Biotherapeutics has raised KRW11.5bn ($10m) in Series A funding from a consortium of domestic venture capital firms, paving a way for the company to accelerate development of its first-in-class inflammatory immune disorder therapy candidate.

The consortium includes LB Investment, KB Investment, HB Investment, SV Investment, KTB Network and Lifecore Partners.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Focus On Asia

More from Scrip

Compass Pathways’ Antidepressant Advances In An Increasingly Tough Psychedelic Market

 
• By Manas Mishra

Psychedelics appear to be in vogue after years of being relegated to alternative medicine. But investor pushback after the highly anticipated release of Phase III trial data by Compass Pathways reveals an increasingly high bar for development.

Eolo Pharma Advances In Obesity With Thermogenesis Approach

 
• By Aakash Babu

Emerging Company Profile: Early-stage biotech Eolo will seek cash and deals for its novel obesity drug SANA after positive Phase I results for weight loss, lean muscle mass preservation and fat mass reduction.

BioMarin’s Roctavian Continues to Shine In Hemophilia A Despite Commercial Woes

 
• By Sushmita Panda

Roctavian shows durable bleed control and safety over five years, but high costs and access hurdles limit its commercial outlook.